$1.13
-0.02-1.74%
Pre-Market: 8:01 AM EDT
Comments
Loading...
ZyVersa Therapeutics (ZVSA) Forecast
NewsEarningsZyVersa Therapeutics (ZVSA) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary
ZyVersa Therapeutics Stock (NASDAQ: ZVSA) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy ZyVersa Therapeutics (ZVSA) stock?
You can purchase shares of ZyVersa Therapeutics (NASDAQ:ZVSA) through any online brokerage.
Who are ZyVersa Therapeutics (ZVSA) competitors?
Other companies in ZyVersa Therapeutics’s space includes: Dermata Therapeutics (NASDAQ:DRMA), Bone Biologics (NASDAQ:BBLG), Entero Therapeutics (NASDAQ:ENTO), Quoin Pharmaceuticals (NASDAQ:QNRX) and Qualigen Therapeutics (NASDAQ:QLGN).
What is the forecast, or price target, for ZyVersa Therapeutics (ZVSA) stock?
ZyVersa Therapeutics has a consensus price target of $12.00.
What is the current price for ZyVersa Therapeutics (ZVSA)?
The stock price for ZyVersa Therapeutics (NASDAQ: ZVSA) is $1.13 last updated November 21, 2024 at 8:01 AM EST.
Does ZyVersa Therapeutics (ZVSA) pay a dividend?
There are no upcoming dividends for ZyVersa Therapeutics.
When is ZyVersa Therapeutics (NASDAQ:ZVSA) reporting earnings?
ZyVersa Therapeutics’s Q3 earnings are confirmed for Thursday, November 14, 2024.
Is ZyVersa Therapeutics (ZVSA) going to split?
There is no upcoming split for ZyVersa Therapeutics.
What sector and industry does ZyVersa Therapeutics (ZVSA) operate in?
ZyVersa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.